Search Results - "Reman, O."

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association by Renneville, A, Boissel, N, Nibourel, O, Berthon, C, Helevaut, N, Gardin, C, Cayuela, J-M, Hayette, S, Reman, O, Contentin, N, Bordessoule, D, Pautas, C, Botton, S de, Revel, T de, Terre, C, Fenaux, P, Thomas, X, Castaigne, S, Dombret, H, Preudhomme, C

“…Recently, DNA methyltransferase 3A ( DNMT3A ) mutations have been identified in acute myeloid leukemia (AML), the highest frequency being found within…”
Get full text

Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases by BAREAU, Benoit, REY, Jérôme, LAMY, Thierry, HAMIDOU, Mohamed, DONADIEU, Jean, MORCET, Jeff, REMAN, Oumedaly, SCHLEINITZ, Nicolas, TOURNILHAC, Olivier, ROUSSEL, Mikael, FEST, Thierry

“…Large granular lymphocyte leukemia is a rare lymphoproliferative disorder associated with autoimmune diseases and impaired hematopoiesis. This study describes…”
Get full text

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM by Robin, M, Porcher, R, Adès, L, Raffoux, E, Michallet, M, François, S, Cahn, J-Y, Delmer, A, Wattel, E, Vigouroux, S, Bay, J-O, Cornillon, J, Huynh, A, Nguyen, S, Rubio, M-T, Vincent, L, Maillard, N, Charbonnier, A, de Latour, R P, Reman, O, Dombret, H, Fenaux, P, Socié, G

“…Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the only a curative treatment in patients with higher risk myelodysplastic syndrome…”
Get full text

Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial by Chantepie, S.P., Mear, J.B., Briant, A.R., Vilque, J.P., Gac, A.C., Cheze, S., Girault, S., Turlure, P., Marolleau, J.P., Lebon, D., Charbonnier, A., Jardin, F., Lenain, P., Peyro-Saint-Paul, L., Abonnet, V., Dutheil, J.J., Chene, Y., Bazin, A., Reman, O., Parienti, J.J.

“…Retrospective studies in hematological unit have suggested that single red blood cell (1-RBC) unit transfusion policy may reduce the number of RBC used without…”
Get full text

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial by TAVERNIER, E, BOIRON, J.-M, TOURNILHAC, O, BUZYN, A, REMAN, O, CHARRIN, C, BOUCHEIX, C, GABERT, J, LHERITIER, V, VERNANT, J.-P, DOMBRET, H, THOMAS, X, HUJUET, F, BRADSTOCK, K, VEY, N, KOVACSOVICS, T, DELANNOY, A, FEGUEUX, N, FENAUX, P, STAMATOULLAS, A

“…Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of…”
Get full text

Hematogones: An overview by Chantepie, S.P, Cornet, E, Salaün, V, Reman, O

“…Abstract Hematogones were initially described as mysterious cells in bone marrow smears more than 70 years ago. These cells are normal bone marrow B-lymphocyte…”
Get full text

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group by TAKSIN, A.-L, LEGRAND, O, GARDIN, C, VARET, B, DE BOTTON, S, POUSSET, F, FARHAT, H, CHEVRET, S, DOMBRET, H, CASTAIGNE, S, RAFFOUX, E, DE REVEL, T, THOMAS, X, CONTENTIN, N, BOUABDALLAH, R, PAUTAS, C, TURLURE, P, REMAN, O

“…Pivotal phase II studies in acute myeloblastic leukemia (AML) patients in first relapse have used gemtuzumab ozogamicin (GO) (Mylotarg) at a dose of 9 mg/m(2)…”
Get full text

Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles by Reboursiere, Emilie, Fouques, H., Maigne, G., Johnson, H., Chantepie, S., Gac, A. C., Reman, O., Macro, M., Benabed, K., Troussard, X., Damaj, G., Cheze, S.

“…Splenectomy remains the preferred treatment for chronic immune thrombocytopenia (ITP) after corticosteroid failure, despite the risks of despite surgical…”
Get full text

Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation by Delapierre, B., Reman, O., Dina, J., Breuil, C., Bellal, M., Johnson-Ansah, H., Gac, A.C., Damaj, G., Chantepie, S.

“…The most used preemptive therapy for Epstein Barr virus reactivation post allogeneic hematopoietic stem cell (HSCT) transplant is Rituximab, 375 mg/m2, once…”
Get full text

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC by Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, Le Gouill, S

“…Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell…”
Get full text

Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy by Chantepie, S P, Michallet, M, Blaise, D, Maury, S, Deconinck, E, Tabrizi, R, Contentin, N, Mohty, M, Nguyen, S, Lioure, B, Raus, N, Peffault de Latour, R, Yakoub-Agha, I, Reman, O

Get full text

A retrospective series of gut aspergillosis in haematology patients by Kazan, E., Maertens, J., Herbrecht, R., Weisser, M., Gachot, B., Vekhoff, A., Caillot, D., Raffoux, E., Fagot, T., Reman, O., Isnard, F., Thiebaut, A., Bretagne, S., Cordonnier, C.

“…Gut invasive aspergillosis is an extremely rare infection in immunocompromised patients. The goal of this retrospective multicentre study is to report on cases…”
Get full text

Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group by de Botton, S, Fawaz, A, Chevret, S, Dombret, H, Thomas, X, Sanz, M, Guerci, A, San Miguel, J, de la Serna, J, Stoppa, A M, Reman, O, Stamatoulas, A, Fey, M, Cahn, J Y, Sotto, J J, Bourhis, J H, Parry, A, Chomienne, C, Degos, L, Fenaux, P

“…To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT)…”
Get full text

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) by Ghesquières, H., Ferlay, C., Sebban, C., Perol, D., Bosly, A., Casasnovas, O., Reman, O., Coiffier, B., Tilly, H., Morel, P., Van den Neste, E., Colin, P., Haioun, C., Biron, P., Blay, J.-Y.

“…This prospective multicentric phase II study aimed to confirm the results of the C5R protocol of high-dose methotrexate (MTX)-based chemotherapy (CT) for…”
Get full text

OUTCOME AND TREATMENT OF RELAPSING EARLY PET NEGATIVE PATIENTS INCLUDED IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA by Gac, A., Chartier, L., Girinsky, T., Gotti, M., Lazarovici, J., Aurer, I., Musto, P., Damaj, G., Federico, M., Fortpied, C., Raemaekers, J., Meignan, M., Hutchings, M., Versati, A., Andre, M., Reman, O.

Get full text

Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: A single-center experience by Chantepie, S.P, Gac, A.C, Reman, O

“…Abstract In reduced-toxicity conditioning hematopoietic stem cell transplantation, several studies failed to demonstrate the superiority of one conditioning…”
Get full text

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study by DELANNOY, A, DELABESSE, E, TURLURE, P, REMAN, O, DELAIN, M, ISNARD, F, COSO, D, RABY, P, BUZYN, A, CAILLERES, S, DARRE, S, FOHRER, C, LHERITIER, V, SONET, A, BILHOU-NABERA, C, BENE, M.-C, DOMBRET, H, BERTHAUD, P, THOMAS, X, CASTAIGNE, S, RIGAL-HUGUET, F, RAFFOUX, E, GARBAN, F, LEGRAND, O, BOLOGNA, S, DUBRUILLE, V

“…Acute lymphoblastic leukemia (ALL) in the elderly is characterized by its ominous prognosis. On the other hand, imatinib has demonstrated remarkable, although…”
Get full text

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia by Renneville, A, Boissel, N, Helevaut, N, Nibourel, O, Terré, C, Pautas, C, Gardin, C, Thomas, X, Turlure, P, Reman, O, Berthon, C, Dombret, H, Castaigne, S, Preudhomme, C

Get full text

Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group by THOMAS, X, RAFFOUX, E, LE, Q.-H, QUESNEL, B, CORDONNIER, C, BOURHIS, J.-H, ELHAMRI, M, FENAUX, P, PREUDHOMME, C, MICHALLET, M, CASTAIGNE, S, DOMBRET, H, DE BOTTON, S, PAUTAS, C, ARNAUD, P, DE REVEL, T, REMAN, O, TERRE, C, CORRONT, B, GARDIN, C

“…In a multicenter trial, 259 young adults (15-49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential…”
Get full text

Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire by Chantepie, S P, Mohty, M, Tabrizi, R, Robin, M, Deconinck, E, Buzyn, A, Contentin, N, Raus, N, Lhéritier, V, Reman, O

“…To assess the role of hematopoietic SCT (HSCT) in adult ALL patients with central nervous system involvement at diagnosis, we retrospectively analyzed 90…”
Get full text